Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects

Inclusion Criteria: * Body weight between 50 and 90 kg with a body mass index between 19 and \<30 kg/m2 * No clinically relevant findings in the medical history, laboratory examinations and physical examination, especially with regard to cardiovascular system, liver function test, bilirubin values and the skin * No clinical relevant pathological findings in electrocardiogram (ECG) * Normal blood pressure (BP, syst. 100 to 140 mmHg, diast. 60 to 90 mmHg) and pulse rate (between 50 and 90 beats/min) in sitting position * Voluntarily signed informed consent after full explanation of the study to the participant Exclusion Criteria: * Treatment with any other investigational product in the last 60 days before the day of randomization into the study * Regular use of medication in the last 60 days before the day of randomization into the study except of oral contraceptives in female participants * Treatment in the 60 days before the day of randomization into the study with any drug known to have a well-defined potential for toxicity to a major organ, or any substance which is known to induce or inhibit hepatic drug metabolism (including general anesthetics) * Any drug intake (including over-the-counter remedies) in the 2 weeks before the day of randomization into the study, unless the investigator considers a drug intake to be clinically irrelevant for the purpose of this study * Any acute or chronic illness or clinically relevant findings in the pre-study examination * Presence, history or sequelae of gastrointestinal (e.g. peptic ulcer), liver or kidney disease, or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs * History of hypersensitivity to the investigational product * History or presence of abnormalities of the vascular bed * History or presence of a dermatologic disease or skin lesions, particular in the area chosen for flush measurement * History of allergy or hypersensitivity to other drugs or to food constituents * History of other allergic diseases or hypersensitivity, unless the investigator considers it to be clinically irrelevant for the purpose of this study * Blood donation of \>400 ml in the 60 days before the day of randomization into the study * Smoking * Positive result in urine screen for drugs of abuse or in alcohol breath test * Known or suspected to be drug-dependent, including consumption of \>30 g alcohol per day * Pregnancy or lactation